論文 - 詳細
| RRC ID | 64099 |
|---|---|
| 著者 | Watanabe K, Toji S, Ohtake J, Nakano K, Satoh T, Kitamura H, Nishimura T. |
| タイトル | Establishment of a stable T lymphoma cell line transduced with HLA-A*24:02-restricted WT1-specific TCR genes and its application to antigen-specific immunomonitoring. |
| ジャーナル | Biomed Res |
| Abstract |
Wilms' tumor gene 1 (WT1) has been proposed as an attractive target for cancer immunotherapy. A natural 9-mer peptide (CYTWNQMNL), which bound to human leukocyte antigen (HLA)-A*24:02, was identified from among WT1-specific cytotoxic T lymphocyte (CTL) epitopes. This natural WT1 CTL epitope peptide was further modified (CMTWNQMNL) to enhance its binding affinity to HLA-A*24:02. This modified WT1 CTL epitope peptide was superior to the natural peptide for inducing HLA-A*24:02-restricted WT1-specific CTLs. Here we induced several WT1 CTLs that reacted with both modified and natural WT1 tetramers from peripheral blood mononuclear cells. Then, T-cell receptor (TCR) genes were isolated from these WT1 CTLs to determine their Vα and Vβ usage. These TCR genes were transduced into human T lymphoma cells to establish a stable cell line, SK37, which expressed a WT1-specific TCR. We confirmed that SK37 cells reacted with both modified and natural WT1 tetramers, which indicated that SK37 cells could be a useful tool for WT1 tetramer reagent quality assurance. One the basis of these findings, we propose that this WT1 tetramer, which was quality-assured using established SK37 cells, will contribute to reliable immunomonitoring of tumor-specific CTL responses of cancer patients who receive WT1-targeted cancer vaccine therapy or TCR-gene therapy. |
| 巻・号 | 34(1) |
| ページ | 41-50 |
| 公開日 | 2013-2-1 |
| DOI | 10.2220/biomedres.34.41 |
| PII | DN/JST.JSTAGE/biomedres/34.41 |
| PMID | 23428979 |
| MeSH | Cancer Vaccines Cell Line, Tumor* Cloning, Molecular Epitopes, T-Lymphocyte / genetics Epitopes, T-Lymphocyte / immunology Genes, T-Cell Receptor / genetics* Genes, Wilms Tumor* Genetic Therapy HLA-A24 Antigen / immunology* Humans Immunotherapy Leukocytes, Mononuclear Lymphoma, T-Cell / genetics* Lymphoma, T-Cell / immunology T-Lymphocytes, Cytotoxic / immunology T-Lymphocytes, Cytotoxic / metabolism Transduction, Genetic* |
| IF | 1.429 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 5 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | Jurkat |